Full-Time

Director of Segment Marketing & Market Development

Cellanome

Cellanome

51-200 employees

Automated platform for live single-cell assays

Compensation Overview

$190k - $240k/yr

San Mateo, CA, USA + 1 more

More locations: San Diego, CA, USA

In Person

On-site role based in Foster City or San Diego; up to 30% travel may be required.

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
Product Management
Cell Biology
Marketing

Get referred to Cellanome

See people who can refer or advise you

Requirements
  • Typically requires a minimum of 15 years of related experience with a Bachelor’s degree; or 12 years and a Master’s degree; or a PhD with 8 years experience; or equivalent experience.
  • Deep fluency in immunology, neurobiology, immune-oncology, functional screening, cell biology, single-cell genomics, and/or functional cell assays.
  • Demonstrated ability to build a market narrative from scratch: segment thesis, proof point architecture, and the content stack that moves buyers from awareness to conviction.
  • Exceptional scientific communication skills, with the ability to produce content that working biologists read and trust.
  • Track record of driving cross-functional alignment without direct authority: getting Scientific Affairs, Sales, and Product moving in the same direction on shared evidence and narrative priorities.
  • Experience producing senior-quality output independently, without a large team or agency infrastructure to rely on.
  • Demonstrated ability to perform the essential duties of the position with or without reasonable accommodations.
Responsibilities
  • Develop and maintain application area narratives that articulate the problem, limitations of status quo, Cellanome advantage, supporting proof, and urgency for each market segment.
  • Partner with Corporate Marketing on segment GTM strategy to co-design and align segment-level market theses with Cellanome’s overarching corporate brand, theme calendar, and demand generation engine.
  • Lead presence buildout in key application areas in close partnership with Applications Product Management, R&D, and Scientific Affairs to ensure narratives are scientifically grounded and commercially sharp.
  • Drive high-authority content creation by owning the end-to-end segment content strategy and authoring specific, data-grounded assets (including blog posts, application area pages, conference presentations, ROI frameworks, and case studies) tailored for a skeptical scientific audience.
  • Collaborate closely with Corporate Marketing to optimize segment content for high-impact channel distribution, and with Applications and Platform Product Management on launches, competitive positioning, product- and technology- level content and sales enablement.
  • Identify and support key opinion leaders (KOL) & early access placement sites who can open target markets and build relationships that generate credible, public proof points.
  • Structure collaborations and publications to support market adoption in partnership with Collaboration Scientists, Scientific Affairs, the account teams, and leadership.
  • Own the marketing side of select KOL relationships, ensuring visibility and impact of collaborations across channels.
  • Develop and maintain segment-specific sales enablement materials including talk tracks, objection handling guides, qualification criteria, and "why now, why us" framing for each application area.
  • Partner with Sales on market development, early funnel building, and specific opportunities as appropriate.
  • Maintain a current view of key segment landscapes, shifting market dynamics and customer needs, and emerging application areas.
  • Synthesize intelligence into actionable inputs for Sales, Product, and leadership with clear implications and recommended actions.
  • Strong presentation and communication skills.
  • Ability to travel up to 30% of working time away from work location, may include overnight and/or weekend travel at times.
  • Ability to work in front of a computer screen and/or perform typing for approximately 90% of a typical working day.
Desired Qualifications
  • Experience building GTM infrastructure for an emerging or nascent category, not just executing playbooks for established markets.
  • Fluency with AI tools as a practical force multiplier for research, drafting, and content production.
  • Experience structuring or influencing scientific collaborations and KOL relationships for commercial or market development purposes.

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Company Size

51-200

Company Stage

Series C

Total Funding

$276.9M

Headquarters

Foster City, California

Founded

2020

Get referred to Cellanome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Psomagen added the R3200 on March 26, 2026, validating external demand.
  • Cellanome showcased live-cell analysis marrying imaging and sequencing at AGBT 2026.
  • Cellanome raised $75.9 million on June 22, 2026, extending runway.

What critics are saying

  • 10x Genomics and other single-cell vendors already dominate adjacent workflows.
  • Cellanome still lacks proof of broad customer adoption beyond Psomagen and conferences.
  • If 2026 spending misses hardware sales, the platform becomes an expensive science project.

What makes Cellanome unique

  • Cellanome links longitudinal live-cell imaging to single-cell transcriptomics from the same cells.
  • Its CellCage micro-3D-printed enclosures isolate cells while drugs and antibodies flow.
  • R3200 captures morphology, phenotype, and RNA on identical live cells.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

401(k) Retirement Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

58%

2 year growth

0%
U.S. Securities and Exchange Commission
Jul 17th, 2026
EDGAR Filing Documents for 0000905148-26-003005

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659

Intelligence360 News
Jul 17th, 2026
Cellanome files to raise $75.9M for live-cell imaging and single-cell transcriptomics platform

Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.

The Business Journals
Jan 30th, 2024
Peninsula startup with Illumina roots lands $150 million to peer deeper into cells

A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.

The Business Journals
Dec 8th, 2021
Former Illumina execs, Grail co-founder raise $21M for biotech startup

Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.